Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDP-4 in Dry Eye Disease
NCT03889886Phase 2Completed
- Sponsor
- Silk Technologies, Ltd.
- Start
- Apr 2019
- Primary completion
- Oct 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amlisimod in dry eye disease (DED) (4 arms), sponsored by Silk Technologies, Ltd. Primary endpoint: Symptom Assessment in Dry Eye Questionnaire at 84 days. Started Apr 2019; status: completed.
02
Drugs
amlisimod
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT03889886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03889886.